Literature DB >> 90971

Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine?

M A Moskowitz, J F Reinhard, J Romero, E Melamed, D J Pettibone.   

Abstract

The headache phase of migraine may develop as the result of an abnormal interaction (and perhaps an abnormal release) of vasoactive neurotransmitters from terminals of the trigeminal nerve with large intracranial and extracranial blood-vessels. These blood-vessels, which dilate during the headache phase of migraine, are thought to receive axonal projections from all three divisions of the trigeminal nerve. Substance P, a potent vasodilating peptide, seems to be released from trigeminal nerve endings in response to nervous stimulation and is involved in the transmission of painful stimuli within the periphery. The vasoactive molecule serotonin, implicated in the pathogenesis of migraine, coexists with substance P in some terminals of the central nervous system and is present within the trigeminal ganglia. Within this nerve serotonin may modulate the function of primary sensory neurons. The abnormal release of substance P or as yet unidentified peptides or other transmitters from the fifth cranial nerve may explain both the hemicranial pain and the vasodilation which are characteristic of the headache of migraine.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 90971     DOI: 10.1016/s0140-6736(79)92692-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  37 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

Review 2.  Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches.

Authors:  Peter J Goadsby
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  The TRPA1 channel in migraine mechanism and treatment.

Authors:  S Benemei; C Fusi; Gabriela Trevisan; Pierangelo Geppetti
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

4.  Therapy of Migraine Headache in Cancer Patients.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

5.  Disturbances in ocular sympathetic function and facial blood flow in unilateral migraine headache.

Authors:  P D Drummond
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154

6.  Possible sites of action of the new calcitonin gene-related peptide receptor antagonists.

Authors:  Sajedeh Eftekhari; Lars Edvinsson
Journal:  Ther Adv Neurol Disord       Date:  2010-11       Impact factor: 6.570

Review 7.  Migraine and the trigeminovascular system-40 years and counting.

Authors:  Messoud Ashina; Jakob Møller Hansen; Thien Phu Do; Agustin Melo-Carrillo; Rami Burstein; Michael A Moskowitz
Journal:  Lancet Neurol       Date:  2019-05-31       Impact factor: 44.182

8.  A non-peptide NK1-receptor antagonist, RP 67580, inhibits neurogenic inflammation postsynaptically.

Authors:  S M Moussaoui; F Montier; A Carruette; J C Blanchard; P M Laduron; C Garret
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

9.  GABAA-receptor-mediated effects of progesterone, its ring-A-reduced metabolites and synthetic neuroactive steroids on neurogenic oedema in the rat meninges.

Authors:  V Limmroth; W S Lee; M A Moskowitz
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

10.  Further characterization of the putative 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater.

Authors:  M G Buzzi; M A Moskowitz; S J Peroutka; B Byun
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.